Showing 1 - 2 results of 2 for search 'A. Rawstron', query time: 0.02s Refine Results
  1. 1
    P673: DEPLETION AND RECOVERY OF NORMAL B-CELLS DURING AND AFTER TREATMENT WITH CHEMOIMMUNOTHERAPY, IBRUTINIB OR VENETOCLAX.

    P673: DEPLETION AND RECOVERY OF NORMAL B-CELLS DURING AND AFTER TREATMENT WITH CHEMOIMMUNOTHERAPY, IBRUTINIB OR VENETOCLAX. by A. Rawstron, N. Webster, A. Pitchford, S. Dalal, A. Bloor, R. de Tute, A. Hockaday, S. Jackson, D. Cairns, N. Greatorex, D. Allsup, T. Munir, P. Hillmen

    Published 2022-06-01
    Get full text
    Article
  2. 2
    S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL

    S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE II... by P. Hillmen, A. Pitchford, A. Bloor, A. Pettitt, P. Patten, F. Forconi, A. Schuh, C. Fox, N. Elmusharaf, S. Gatto, B. Kennedy, J. Gribben, N. Pemberton, O. Sheehy, G. Preston, D. Howard, A. Hockaday, D. Cairns, S. Jackson, N. Greatorex, N. Webster, S. Dalal, J. Shingles, K. Cwynarski, S. Paneesha, D. Allsup, A. Rawstron, T. Munir

    Published 2022-06-01
    Get full text
    Article

Search Tools: